|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 美国临床肿瘤学会IV期非小细胞肺癌化疗的临床实践指南更新显示文摘本文旨在为IV期非小细胞肺癌患者的治疗提供更新版推荐。本文资料检索源自2002年以来公布的相关随机试验文献。此指南范围限于化疗与生物治疗。更新委员会对这些文献进行了总结并提供了推荐更新。162篇文献符合标准被纳入参考。本推荐基于可改善总生存期的治疗方法。仅改善无进展生存期的治疗方法推动了对毒性及生存质量的监测。对于体力状态评分为0分或1分患者的一线治疗,可推荐以铂类为基础的细胞毒性药物的两药联用。对铂类治疗有禁忌的患者,可采用非铂类细胞毒性两药联合。对于体力状态评分为2分的患者,单一细胞毒性药物即可。对于疾病进展或经过4个周期的治疗仍对治疗无反应的患者,应停止一线细胞毒性化疗。即使在6个周期后患者对治疗仍有反应,亦应停止两药细胞毒性化疗。对于伴有明确的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变的患者,可推荐一线采用吉非替尼治疗;对于EGFR突变为阴性或不明确的患者,细胞毒性化疗更佳。除具有特定临床特征的患者外,可推荐贝伐单抗与卡铂-紫杉醇联用。对于通过免疫组化证实EGFR阳性的肿瘤患者,可推荐西妥昔单抗与顺铂-长春瑞滨联用。多西紫杉醇、厄洛替尼、吉非替尼或培美曲塞被推荐作为二线治疗。对于未曾接受过厄洛替尼或吉非替尼治疗的患者,可推荐厄洛替尼作为三线治疗。现有数据不足以推荐常规三线采用细胞毒性药物。已有的证据也不足以推荐常规应用分子标记物选择化疗。 | Christopher G. AZZOLI Sherman Baker JR Sarah TEMIN William PAO Timothy ALIFF Julie BRAHMER David H. JOHNSON Janessa L. LASKIN Gregory MASTERS Daniel MILTON Luke NORDQUIST David G. PFISTER Steven PIANTADOSI Joan H. SCHILLER Reily SMITH Thomas J. SMITH John R. STRAWN David TRENT Giuseppe GIACCONE 丁燕(翻译) 南娟(翻译) 刘谦(翻译) 周清华(校对) 陈军(校对) | 2010 | 中国肺癌杂志2010，13，3： | 43 |
| 2 | 急性缺血性卒中患者早期处理指南:美国心脏协会/美国卒中协会对医疗专业人员的指南显示文摘背景和目的作者提供了关于成年急性缺血性卒中患者评估和治疗方面的现有证据和处理推荐的一份概述。目标读者为涉及急性缺血性卒中患者发病48h内诊治的院前诊疗人员、医生、综合医疗保健人员和医院管理者。该指南将取代先前的2007年版指南及其2009年更新版。方法著述委员会成员由美国卒中协会卒中委员会的科学声明监督委员会指定,代表各个领域的医疗专家。在形成共识的整个过程中,严格遵循美国心脏协会的利益冲突原则。委员会成员被分配给与其专业领域相关的内容,对卒中文献进行回顾,重点为前一版指南发表之后的文献,然后按照美国心脏协会卒中委员会的证据强度分级方案起草推荐意见。结果本指南的目的是减少卒中相关的残疾和死亡。本指南支持卒中医疗体系的全局性概念以及从患者识别、急救医疗服务激活、转送和分诊到急诊室和卒中单元内最初数小时诊治的卒中诊治细节。本指南讨论了早期卒中评估和一般治疗、缺血性卒中治疗、特殊干预措施,如再灌注策略以及脑复苏的一般生理学干预原则。结论由于许多推荐意见基于有限的证据,还迫切需要对急性缺血性卒中的治疗做进一步的研究。 | Edward C. Jauch Jeffrey L. Saver Harold P. Adams Askiel Bruno J.J. (Buddy) Connors Bart M. Demaerschalk Pooja Khatri Paul W. McMullan Jr, Adnan I. Qureshi Kenneth Rosenfield Phillip A. Scott Debbie R. Summers David Z. Wang Max Wintermark Howard Yonas 李海峰(译) 岳耀先(译) 王琦(译) 张贤军(译) 丁晓君(译) | 2013 | 国际脑血管病杂志2013，21，7： | 17 |
| 3 | 将卒中纳入心血管风险预测工具美国心脏协会/美国卒中协会对医疗卫生专业人员的声明显示文摘背景和目的目前美国针对心血管事件风险预测以及一级和二级预防的指南声明均使用绝对风险估计值来识别血管事件高危患者以及可从特定干预措施中获益的患者。然而,这些指南并未明确地包括卒中患者。本指南对现有证据和争论进行概述以支持:(1)将卒中(尤其是动脉粥样硬化性卒中)患者纳入心血管病绝对风险增高的患者群体;(2)将卒中纳入血管性疾病风险预测工具的转归预测因素。方法和结果写作组成员由委员会联合主席基于先前在相关领域的研究成果来提名,并得到美国心脏协会(American Heart Association,AHA)卒中委员会科学声明监督委员会以及文稿监督委员会的批准。作者采用系统文献回顾(覆盖1980年1月至2010年3月期间的文献)并参考以往公布的指南、个人资料以及专家观点,以归纳现有证据,提出当前知识的不足,并根据AHA标准对适当的问题制定推荐意见。所有写作组成员均有机会对推荐意见进行评论并批准了最终版本。经广泛的AHA内部同行评议以及卒中委员会领导阶层和科学声明监督委员会的审阅后,最终获得AHA科学咨询和协调委员会的批准。将卒中患者(尤其是动脉粥样硬化性卒中患者)纳入冠状动脉和心血管病绝对高危人群的原因如下。首先,有证据显示,缺血性卒中患者发生致死性和非致死性心肌梗死或猝死的绝对风险增高,10年绝对风险≥20%,这一风险阈值已被一些指南用于定义冠状动脉疾病风险等危症。其次,纳入动脉粥样硬化性卒中的原因与纳入糖尿病、周围血管病、慢性肾脏病以及其他动脉粥样硬化性疾病的原因相同,尽管尚缺乏在所有人群或患者中风险增高的统一证据。再次,缺血性卒中的大动脉粥样硬化性卒中亚型与其他这些疾病的病理生理学机制相同。将卒中纳入高危因素将导致高危人群的数量扩大约10%。然而,由于卒中的异质性,尚不确定其他卒中亚型,包括出血性卒中以及非动脉粥样硬化性卒中亚型,是否应被视为具有相同水平的风险,因此有待进一步研究。鉴于卒中对残疾和死亡的影响、卒中与其他血管性疾病预防措施的相似性以及卒中在某些人群中较冠状动脉疾病更高的重要性,将卒中、心肌梗死和猝死纳入心血管事件风险预测工具的转归预测因素是合适的。美国以外的指南常常将卒中患者纳入心血管高危人群,并将卒中作为心脏终点的一个相关转归事件。结论动脉粥样硬化性卒中患者应被纳入会进一步发生冠状动脉粥样硬化事件的高危患者(10年≥20%)。是否应纳入非动脉粥样硬化卒中亚型尚不确定。对于一级预防,缺血性卒中应被纳入绝对风险评估方案的心血管疾病转归事件。将动脉粥样硬化性卒中作为一个高危因素或者更宽泛地将缺血性卒中视作一种转归事件纳入,可能对心血管病的预防具有重要意义,因为被评定为高危风险的患者数量将大幅增加。 | Daniel T. Lackland Mitchell S.V. Elkind Ralph D'Agostino Sr Mandip S. Dhamoon David C. Goff Jr Randall T. Higashida Leslie A. McClure Pamela H. Mitchell Ralph L. Sacco Cathy A. Sila Sidney C. Smith Jr David Tanne David L. Tirschwell Emmanuel Touze Lawrence R. Wechsler 4:~ 尤寿江(译) 于海龙(译) 刘慧慧(译) 张霞(译) 刘春风(译) | 2012 | 国际脑血管病杂志2012，20，11： | 13 |
| 4 | Bacterial biota in reflux esophagitis and Barrett's esophagus显示文摘AIM: To identify the bacterial flora in conditions such as Barrett's esophagus and reflux esophagitis to determine if they are similar to normal esophageal flora.METHODS: Using broad-range 16S rDNA PCR,esophageal biopsies were examined from 24 patients [9with normal esophageal mucosa, 12 with gastroesophageal reflux disease (GERD), and 3 with Barrett's esophagus].Two separate broad-range PCR reactions were performed for each patient, and the resulting products were cloned.In one patient with Barrett's esophagus, g9 PCR clones were analyzed.RESULTS: Two separate clones were recovered from each patient (total = 48), representing 24 different species, with 14 species homologous to known bacteria,5 homologous to unidentified bacteria, and 5 were not homologous (<97% identity) to any known bacterial 16S rDNA sequences. Seventeen species were found in the reflux esophagitis patients, 5 in the Barrett's esophagus patients, and 10 in normal esophagus patients.Further analysis concentrating on a single biopsy from an individual with Barrett's esophagus revealed the presence of 21. distinct bacterial species. Members of four phyla were represented, including Bacteroidetes,Firmicutes, Proteobacteria, and Actinobacteria.Microscopic examination of each biopsy demonstrated bacteria in intimate association with the distal esophageal epithelium, suggesting that the presence of these bacteria is not transitory.CONCLUSION: These findings provide evidence for a complex, residential bacterial population in esophageal reflux-related disorders. While much of this biota is present in the normal esophagus, more detailed comparisons may help identify potential disease associations. | Zhiheng Pei Liying Yang Richard M Peek Jr Steven M Levine David T Pride Martin J Blaser | 2005 | World Journal of Gastroenterology2005，11，46： | 11 |
| 5 | Selecting suitable solid organ transplant donors: Reducing the risk of donor-transmitted infections显示文摘Selection of the appropriate donor is essential to a successful allograft recipient outcome for solid organ transplantation. Multiple infectious diseases have been transmitted from the donor to the recipient via transplantation. Donor-transmitted infections cause increased morbidity and mortality to the recipient. In recent years, a series of high-profile transmissions of infections have occurred in organ recipients prompt-ing increased attention on the process of improving the selection of an appropriate donor that balances the shortage of needed allografts with an approach that mitigates the risk of donor-transmitted infection to the recipient. Important advances focused on improving donor screening diagnostics, using previously excluded high-risk donors, and individualizing the selection of allografts to recipients based on their prior infection history are serving to increase the donor pool and improve outcomes after transplant. This article serves to review the relevant literature surrounding this topic and to provide a suggested approach to the selection of an appropriate solid organ transplant donor. | Christopher S Kovacs Jr Christine E Koval David van Duin Amanda Guedes de Morais Blanca E Gonzalez Robin K Avery Steven D Mawhorter Kyle D Brizendine Eric D Cober Cyndee Miranda Rabin K Shrestha Lucileia Teixeira Sherif B Mossad | 2014 | World Journal of Transplantation2014，4，2： | 7 |
| 6 | 动脉瘤性蛛网膜下腔出血患者的重症监护处理:神经危重症监护学会多学科共识会议的推荐意见显示文摘蛛网膜下腔出血(subarachnoidhemorrhage,SAH)是一种可对中枢神经系统造成毁灭性打击并对其他多个器官产生显著影响的急性脑血管病。SAH患者被常规收入重症监护病房并由多学科团队进行治疗。由于高质量研究证据的缺乏,使得治疗方法各异,可供选择的指导意见不多。现有的指南主要强调危险因素、预防、自然史以及再出血的预防,很少涉及SAH患者的重症监护问题。美国神经危重症监护学会组织了一次国际性多学科共识会议来探讨SAH的重症监护处理。根据发表的文章和研究领域,此次会议召集了来自欧洲和北美地区的神经重症监护科、神经外科、神经内科、介入神经放射科和神经麻醉科方面的专家。根据临床经验和制定实践指南方面的经验,选择4名经验丰富的神经重症监护专家组成评判委员会。应用推荐分级的评估、制定与评价(GradesofRecommendationsAssessment,DevelopmentandEvaluation,GRADE)系统进行文献回顾,结合参会者的经验、评判委员会的审评以及文献讨论产生推荐意见。应用GRADE系统制定推荐意见,其制定原则不仅强调研究资料的质量,而且还重视利弊权衡与实践转化。对SAH患者日常处理过程中面临的所有问题均提供指导和推荐意见,即使缺乏高质量的证据。 | Michael N. Diringer Thomas P. Bleck J. Claude Hemphill David Menon Lori Shutter Paul Vespa Nicolas Bruder E. Sander Connolly Jr Giuseppe Citerio Daryl Gress Daniel Hanggi Brian L. Hoh Giuseppe Lanzino Peter Le Roux Alejandro Rabinstein, Erich Schmut zhard Nino Stocchetti Jose I. Suarez Miriam Tresgiari Ming-Yuan Tseng Mervyn D. I. Vergouwen Stefan Wolf Gregory Zip fel 田飞(译) 宿 英英(译) | 2013 | 国际脑血管病杂志2013，21，5： | 5 |
| 7 | Approach to medical therapy in perianal Crohn’s disease显示文摘Perianal Crohn’s disease remains a challenging condition to treat and can have a substantial negative impact on quality of life.It often requires combined surgical and medical interventions.Anti-tumor necrosis factor(anti-TNF)therapy,including infliximab and adalimumab,remain preferred medical therapies for perianal Crohn’s disease.Infliximab has been shown to be efficacious in improving fistula closure rates in randomized controlled trials.Clinicians can be faced with a number of questions relating to the optimal use of anti-TNF therapy in perianal Crohn’s disease.Specific issues include evaluation for the presence of perianal sepsis,the treatment target of therapy,the ideal time to commence treatment,whether additional medical therapy should be used in conjunction with anti-TNF therapy,and the duration of treatment.This article will discuss key studies which can assist clinicians in addressing these matters when they are considering or have already commenced anti-TNF therapy for the treatment of perianal Crohn’s disease.It will also discuss current evidence regarding the use of vedolizumab and ustekinumab in patients who are failing to achieve a response to anti-TNF therapy for perianal Crohn’s disease.Lastly,new therapies such as local injection of mesenchymal stem cell therapy will be discussed. | Abhinav Vasudevan David H Bruining Edward V Loftus Jr William Faubion Eric C Ehman Laura Raffals | 2021 | World Journal of Gastroenterology2021，27，25： | 4 |
| 8 | AIDS-associated plasmablastic lymphoma presenting as a poorly differentiated esophageal tumor: A diagnostic dilemma显示文摘Plasmablastic lymphoma (PBL) is a rare form of diffuse large B-cell lymphoma characterized by weak/absent expression of conventional B-cell markers and strong expression of plasma cell markers. It is strongly associated with human immunodeficiency virus (HIV) and Epstein Barr virus infection, and shows an unusual tropism to the oral cavity. Herein we describe a patient with AIDS who presented with weight loss and dysphagia owing to a large gastroesophageal mass. His radiographic and endoscopic findings and long history of cigarette consumption suggested carcinoma. Biopsy demonstrated a poorly differentiated tumor stained negatively to routine lymphoid markers including CD20. However, gene rearrangement studies confirmed a B-cell process and a more detailed immunohistochemical analysis revealed the cells stained positively for CD138 (plasma cell antigen). These findings were diagnostic of PBL. Our report reviews the wide differential diagnosis of PBL and underscores the importance of a broad array of viral and molecular studies needed to establish this diagnosis. | Deepthi Mani Donald G Guinee Jr David M Aboulafia | 2008 | World Journal of Gastroenterology2008，14，27： | 4 |
| 9 | 大鼠中央杏仁核5-HT_3受体参与胸腺功能调制(英文)显示文摘本研究旨在探讨大鼠中央杏仁核(central amygdala,CeA)内5-HT3受体激动之后,对丝裂原刀豆球蛋白A(concanavalin A,ConA)刺激的胸腺细胞增殖反应的影响,及其潜在的神经内分泌调节环路。分别经大鼠腹腔(intraperitoneal,i.p.)、双侧侧脑室(intracerebroventricle,i.c.v.)和双侧CeA(intracentral amygdala,i.c.a.)注射选择性5-HT3受体激动剂1-phenylbiguanide(PBG),同时制备正常大鼠胸腺细胞悬液与不同浓度FBG(1×10-8~1×10-5mol/L)体外共同孵育。经MTT法测定显示,无论有无ConA刺激,正常大鼠离体胸腺细胞在与PBG(1×10-8~1×10-5mol/L)体外共同孵育时其增殖反应均不受后者影响;PBG i.p.(每天0.5 mg/kg,连续5 d)对ConA刺激的胸腺细胞的增殖反应亦无影响,而PBG i.c.v.(每天10μg/侧,连续5 d)则显著增强之;当PBG i.c.a.(每天1.0μg,侧,1 d或连续3、5、7 d)时,ConA刺激的胸腺细胞的增殖反应于给药后第1天即开始增强且日益显著,第5天达到高峰,第7天则趋于减弱。在给予PBG 5 min前相同给药部位先给予5-HT3受体拮抗剂tropisetron(TRP)预处理可逆转PBG的促胸腺细胞增殖效应。免疫组织化学SABC法检测显示,PBG(1.0μg/侧,i.c.a.)单次给药后各脑区可相继出现大量c-Fos阳性细胞(CeA:1 h;海马及皮层:1~2 h;下丘脑:4 h;中脑导水管周围灰质:8 h),并迅速达到各自高峰(CeA: 1 h;海马及皮层:2 h;下丘脑:4 h),与相应的生理盐水对照组及TRP预处理组相比均有显著性差异。随后,这一表达在各脑区中逐步减弱并消失(CeA:4 h;海马、皮层及下丘脑:8 h)。由此推论,大鼠CeA内5-HT3受体至少可部分通过边缘系统-皮层-下丘脑-中脑导水管周围灰质这一神经内分泌环路调制胸腺细胞功能。 | 徐民 陈伟强 王基平 David JR Foster 许德义 | 2007 | 生理学报2007，59，1： | 3 |
| 10 | A randomized trial comparing the Tennant Biomodulator to transcutaneous electrical nerve stimulation and traditional Chinese acupuncture for the treatment of chronic pain in military service members显示文摘Background:The present investigation tested the efficacy of the Tennant Biomodulator,a novel pain management intervention that uses biofeedback-modulated electrical stimulation,to reduce chronic pain and its psychosocial sequelae in a sample of current and former military service members.The Tennant Biomodulator used on its most basic setting was compared to two commonly used,non-pharmacological pain treatments—traditional Chinese acupuncture and transcutaneous electrical nerve stimulation(TENS)—in a comparative efficacy,randomized,open-label trial.Methods:Participants included 100 active duty and retired service men and women with chronic pain undergoing treatment at the Brooke Army Medical Center in Texas,USA,randomly assigned to receive six,weekly sessions of either Tennant Biomodulator treatment,traditional Chinese acupuncture,or TENS,in addition to usual care.Recruitment was conducted between May 2010 to September 2013.Outcome measures were collected at intake,before and after each treatment session,and at a 1-month follow-up.Intent-to-treat analyses were used throughout,with mixed models used to investigate main effects of group,time,and group×time interactions with consideration given to quadratic effects.Outcomes measured included ratings of chronic pain,pain-related functional disability,and symptoms of post-traumatic stress disorder(PTSD)and depression.Results:On average,regardless of their treatment group,participants exhibited a 16%reduction in pain measured by the Brooke Army Medical Center’s Clinic Pain Log[F(1,335)=55.7,P<0.0001]and an 11%reduction in pain-related disability measured by the Million Visual Analog Scale[MVAS:F(1,84)=28.3,P<0.0001]from baseline to the end of treatment,but no one treatment performed better than the other,and the reductions in pain and pain-related disability were largely lost by 1-month follow-up.Symptoms of PTSD and depression did not change significantly as a function of time or group.Conclusions:Findings build on previous work suggesting that traditional Chinese acupuncture and TENS can reduce pain and its functional sequelae without risks associated with pharmacological pain management.The Tennant Biomodulator used on its most basic setting performs as well as these other interventions.Based on the present findings,large,randomized controlled trials on the Tennant Biomodulator are indicated.Future work should test this device using its full range of settings for pain-related psychological health.Trial registration:Clincialtrials.gov(NCT01752010);registered December 14,2012. | Kimberly S.Peacock Erika Stoerkel Salvatore Libretto Weimin Zhang Alice Inman Michael Schlicher John D.Cowsar Jr David Eddie Joan Walter | 2020 | Military Medical Research2020，7，2： | 3 |
| 11 | Observing the stages of bystander intervention in virtual reality simulation显示文摘BACKGROUND: Understanding bystander reactions to an emergency is an important component of effective training. Four stages of bystander intervention (BI) have been previously described: noticing the situation as a problem, interpreting when it is appropriate to intervene, recognizing personal responsibility to intervene, and knowing how to intervene. Using virtual reality (VR) to simulate emergencies such as sudden cardiac arrest (SCA) can be used to study these stages. METHODS: In a secondary analysis of an observational cohort study, we analyzed bystander self-effi cacy for stages of BI before and after simulated SCA. Each subject participated in a singleplayer, immersive, VR SCA scenario. Subjects interacted with simulated bystanders through voice commands (“call 911”,“get an AED”). Actions taken in scenario, like performing CPR, were documented. Scenario BI actions were compared based on dichotomized comfort/discomfort. RESULTS: From June 2016 to June 2017, 119 subjects participated. Average age was 37±14 years, 44% were female and 46% reported CPR training within 2 years. During the scenario, 98%“noticed the event” and “interpreted it as a problem”, 78%“took responsibility”, and 54%“possessed the necessary skills”. Self-effi cacy increased from pre- to post-scenario: noticing the event increased from 80% to 96%;interpreting as a problem increased from 86% to 97%;taking responsibility increased from 56% to 93%;possessing necessary skills increased from 47% to 63%(P<0.001). CONCLUSION: Self-efficacy to respond to an SCA event increased pre- to post-scenario. Bystanders who reported feeling comfortable “taking responsibility to intervene” during an emergency were more likely to take action during a simulated emergency. | David G. Buckler Alfredo Almodovar Jr Paul Snobelen Benjamin S. Abella Audrey Blewer Marion Leary | 2019 | World Journal of Emergency Medicine2019，10，3： | 2 |
| 12 | SARS-COV-2 infection(coronavirus disease 2019)for the gastrointestinal consultant显示文摘The current pandemic due to the severe acute respiratory syndrome coronavirus 2 has caused an extreme burden for health care systems globally,and the number of cases is expected to continue to increase,at least in the immediate future.The virus is estimated to have infected more than 1.5 million individuals.The available reports suggest that gastrointestinal(GI)involvement in coronavirus disease 2019(COVID-19)is common and in some cases the GI symptoms may precede the respiratory symptoms.In addition to direct effects of severe acute respiratory syndrome coronavirus 2,the infected patients remain at risk for the complications commonly managed by gastroenterology and hepatology consultants.The most commonly reported GI manifestation of COVID-19 is diarrhea,which is reported in a third to up to more than half of the patients.Mild to moderate elevation of the liver enzymes are also common,although no case of acute liver failure has been reported so far.Many of the medications used for treatment of COVID-19 can also be associated with GI symptoms or liver injury and can be included in the differential diagnosis in these patients.Although the diagnosis of the infection is currently based on RNA analysis in respiratory samples,the available literature on fecal shedding of this virus suggests that fecal RNA testing might prove to be a useful diagnostic test.It is reasonable to delay all non-urgent endoscopic procedures during the peak of the pandemic and use additional protective equipment such as N95 respirators during endoscopy while most patients can be considered high risk for having been exposed to the virus. | Kaveh Hajifathalian Srihari Mahadev Robert E Schwartz Shawn Shah Kartik Sampath Felice Schnoll-Sussman Robert S Brown Jr David Carr-Locke David E Cohen Reem Z Sharaiha | 2020 | World Journal of Gastroenterology2020，26，14： | 2 |
| 13 | A new method of puritication of human neutrophils and eosinophils 显示文摘 | Vadas MA David JR Bulterwcrth A | 1979 | J Immunol1979，122，4： | 1 |
| 14 | Digital micropropulsion显示文摘 | David H.Lewish Jr Siegfried W.Janson Ronald B.Cohen | | 0，，80： | 1 |
| 15 | The ecology of medical care revisited显示文摘 | Larry A Green George E Fryer Jr Barbara P Yawn David lanier Susan M Dovey | 2001 | The New England Journal of Medicine2001，334，26： | 1 |
| 16 | Common gait abnormalities of the knee in cerebral palsy显示文摘 | Sutherland DH Davids JR | 1993 | Oin Orthopaedics Related Res1993，，288： | 1 |
| 17 | The effects of soil type and chemical treatment on nickel speciation in refinery enriched soils: A multi-technique investigation显示文摘 | David H McNear Jr Rufus L | 2007 | Geochimiea et Cosmochimica Acta2007，71，： | 1 |
| 18 | The effects of Holocene barrier -island evolution on water table elevations, Hatteras Island, North Carolina, USA 显示文摘 | Willianm P Anderson Jr David G | 2000 | Hydrogeology Journal2000，，8： | 1 |
| 19 | Early Predictors of 15-Year End-Stage Renal Disease in Hypertensive Patients显示文摘 | Jr Perry J. Philip Miller Jane Rossiter Fornoff Jack D. Baty Mohinder P. Sambhi Gale Rutan David W. Moskowitz Sharon E. Carmody | 1995 | Hypertension1995，，4： | 1 |
| 20 | Coronary Heart Disease/Thrombosis/Myocardial-Infarction: Marked Inflammatory Sequelae to Implantation of Biodegradable and Nonbiodegradable Polymers in Porcine Coronary Arteries显示文摘 | Willem J. van der Giessen A. Michael Lincoff Robert S. Schwartz Heleen M.M. van Beusekom Patrick W. Serruys David R. Jr Holmes Stephen G. Ellis Eric J. Topol | 1996 | Circulation1996，，7： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员